| Literature DB >> 28028559 |
Ja Min Byun1, Young Jin Kim2, Taemi Youk3, John Jeongseok Yang4, Jongha Yoo5, Tae Sung Park6.
Abstract
Myeloproliferative neoplasms (MPNs), with an expected increment in number, impose substantial economic and social burdens. To this end, we conducted a nationwide population-based descriptive epidemiology study. We also investigated medical cost associated with MPNs. Prevalence was the highest for essential thrombocythemia (ET) (range 4.1-9.0 per 100,000), followed by polycythemia vera (PV) (range 2.8-5.4 per 100,000) and primary myelofibrosis (PMF) (range 0.5-0.9 per 100,000). ET incurred the highest cumulative total cost at US$35 million and the most frequent hospital visits, while PMF incurred the highest average cost per person at US$5000. The mean hemoglobin level was 16.9 ± 2.2 g/dL for PV males and 15.5 ± 2.7 g/dL for PV females. Further analyses on hemoglobin levels showed the true positive rate of PV from the significantly elevated hemoglobin group (defined as >18.5 g/dL for men and >16.5 g/dL for women) was 3.01% and that of MPNs was 3.1%. Here, we provide the biggest population-based report on MPN epidemiology that can readily be used as a representative Asian data.Entities:
Keywords: Asia; Epidemiology; Medical cost; Myeloproliferative neoplasm
Mesh:
Year: 2016 PMID: 28028559 DOI: 10.1007/s00277-016-2902-9
Source DB: PubMed Journal: Ann Hematol ISSN: 0939-5555 Impact factor: 3.673